Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Cyclic - C2  (3D View)
Global Stoichiometry: Homo 2-mer - A2 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 29.30 kDa 
• Atom Count: 2131 
• Modelled Residue Count: 246 
• Deposited Residue Count: 253 
• Unique protein chains: 1

2OUZ

Crystal Structure of Estrogen Receptor alpha-lasofoxifene complex

• DOI: 10.2210/pdb2OUZ/pdb

• Classification: HORMONE/GROWTH FACTOR
• Organism(s): Homo sapiens
• Expression System: Escherichia coli
• Mutation(s): No 


• Deposited: 2007-02-12 Released: 2007-05-08 
• Deposition Author(s): Vajdos, F.F., Pandit, J.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.00 Å
• R-Value Free: 0.269 
• R-Value Work: 0.199 
• R-Value Observed: 0.202 

Literature

The 2.0 A crystal structure of the ER{alpha} ligand-binding domain complexed with lasofoxifene

Vajdos, F.F., Hoth, L.R., Geoghegan, K.F., Simons, S.P., LeMotte, P.K., Danley, D.E., Ammirati, M.J., Pandit, J.

(2007) Protein Sci 16: 897-905

• PubMed: 17456742 
• DOI: 10.1110/ps.062729207
• Primary Citation of Related Structures:  
  2OUZ


• PubMed Abstract: 
  

Lasofoxifene is a new and potent selective estrogen receptor modulator (SERM). The structural basis of its interaction with the estrogen receptor has been investigated by crystallographic analysis of its complex with the ligand-binding domain of estrogen receptor alpha at a resolution of 2.0 A. As with other SERMs, lasofoxifene diverts the receptor from its agonist-bound conformation by displacing the C-terminal AF-2 helix into the site at which the LXXLL motif of coactivator proteins would otherwise be able to bind. Lasofoxifene achieves this effect by occupying the space normally filled by residue Leu 540, as well as by modulating the conformation of residues of helix 11 (His 524, Leu 525). A well-defined salt bridge between lasofoxifene and Asp 351 suggests that charge neutralization in this region of the receptor may explain the some of the antiestrogenic effects of lasofoxifene. The results suggest general features of ERalpha/SERM recognition, and add a new dimension to efforts to rationalize differences between the biological activity profiles exhibited by these important pharmacological agents.

---

Organizational Affiliation: 

Department of Exploratory Medicinal Sciences, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut 06340-8001, USA. [e-mail]

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Estrogen receptor	A	253	Homo sapiens	Mutation(s): 0  Gene Names: ESR1, ESR, NR3A1
Find proteins for P03372 (Homo sapiens) Explore P03372  Go to UniProtKB:  P03372
NIH Common Fund Data Resources
PHAROS:  P03372 GTEx:  ENSG00000091831

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
C3D	A	(5R,6S)-6-PHENYL-5-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]-5,6,7,8-TETRAHYDRONAPHTHALEN-2-OL C28 H31 N O2 GXESHMAMLJKROZ-IAPPQJPRSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
C3D	IC50:  0.5   nM  BindingDB
C3D	IC50:  4   nM  BindingDB
C3D	EC50:  3.0999999046325684   nM  BindingDB
C3D	IC50:  1.2999999523162842   nM  BindingDB
C3D	IC50:  11   nM  BindingDB
C3D	IC50:  1.399999976158142   nM  BindingDB

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.00 Å
• R-Value Free: 0.269 
• R-Value Work: 0.199 
• R-Value Observed: 0.202 
• Space Group: P 6₅ 2 2

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 58.306	α = 90
b = 58.306	β = 90
c = 275.033	γ = 120

Software Package:

Software Name	Purpose
REFMAC	refinement
PDB_EXTRACT	data extraction
DENZO	data reduction
SCALEPACK	data scaling
AMoRE	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2007-02-12 
• Released Date: 2007-05-08 
Deposition Author(s): Vajdos, F.F., Pandit, J.

Revision History  

• Version 1.0: 2007-05-08
  Type: Initial release
  
• Version 1.1: 2008-05-01
  Changes: Version format compliance
• Version 1.2: 2011-07-13
  Changes: Advisory, Version format compliance
• Version 1.3: 2018-04-04
  Changes: Data collection
• Version 1.4: 2020-01-15
  Changes: Structure summary